Nurosene acquired all of the issued and outstanding securities of NetraMark for a purchase price of CAD$15,000,000 payable as follows to shareholders of NetraMark: (i) 6,148,325 common shares of the Nurosene at a price of approximately $2.09 ("Purchase Shares") representing an amount of CAD$12,850,000 and (ii) CAD$2,150,000 in cash subject to a $200,000 holdback.

As part of a regular series powered by Microsoft, BetaKit interviews prominent Canadian CTOs speaking earnestly on the biggest challenges they face in their role, as well as future technology predictions in their space. Dr. Geraci leads a 10-person team at NetraMark to help pharmaceutical companies with clinical trials and drug development. Together with his team, Dr. Geraci has developed innovative ways of executing machine learning on small data sets as well as quantum machine learning-- the intersection of machine learning and quantum computing. The startup world is new to Dr. Geraci, whose background is in academia. Holding a PhD in mathematics and postdocs in oncology, machine learning, and psychiatry, Dr. Geraci's work as an academic was straightforward in its approach, but required creativity in how to make sense of the data.